Gersthofen, Germany

Andreas Winter

This inventor holds 3 USPTO granted patents and 3 EPO patents. Top assignees: Almac Diagnostics Limited, Almac Diagnostic Services Limited. Active years: 2019-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andreas Winter. Retrieved from https://idiyas.com/inventor/andreas-winter-qe24rlvp

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


 

Average Co-Inventor Count = 13.9

ph-index = 2

Forward Citations = 69(Granted Patents)


Company Filing History:


Years Active: 2019-2021

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Andreas Winter in Cancer Diagnostics

Introduction

Andreas Winter is an accomplished inventor based in Gersthofen, Germany. He has made significant contributions to the field of molecular diagnostics, particularly in cancer detection and treatment responsiveness. With a total of three patents to his name, Winter's work focuses on improving patient outcomes through innovative testing methods.

Latest Patents

One of Winter's latest patents is a molecular diagnostic test for cancer. This invention provides methods and compositions for identifying cancer subtypes that exhibit changes in biomarker expression related to angiogenesis and vascular development. The test is designed to determine whether patients with cancer are clinically responsive or non-responsive to therapeutic regimens before the administration of any anti-angiogenic agents. It can be applied across various cancer types and with different drugs that influence angiogenesis or its signaling pathways. Additionally, this invention serves as a prognostic indicator for certain cancer types, utilizing specific combinations of predictive markers that correlate with treatment responsiveness.

Another notable patent by Winter is a method of using a gene expression profile to assess cancer responsiveness to anti-angiogenic agents. This invention also identifies cancer subtypes responsive to anti-angiogenesis therapeutics, allowing for the classification of patients within these subtypes. Similar to his previous patent, this test can be utilized for various cancer types and drugs affecting angiogenesis. It also functions as a prognostic tool, emphasizing the importance of predictive markers in determining treatment outcomes.

Career Highlights

Throughout his career, Andreas Winter has worked with reputable organizations, including Almac Diagnostics Limited and Almac Diagnostic Services Limited. His experience in these companies has contributed to his expertise in molecular diagnostics and cancer research.

Collaborations

Winter has collaborated with notable professionals in the field, including Denis Paul Harkin and Vitali Proutski. These collaborations have likely enhanced his research and development efforts in cancer diagnostics.

Conclusion

Andreas Winter's innovative contributions to cancer diagnostics through his patents demonstrate his commitment to improving patient care. His work in identifying cancer subtypes and treatment responsiveness is paving the way for more effective therapeutic strategies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…